Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > My patent.

<< Previous

Bullboard Posts

Next >>

Comment by dayxdayon Mar 28, 2021 8:43pm

179 Views

Post# 32896076

RE:RE:RE:My patent.

Votan2015 wrote: Dont pretend you are here to support Claritas and have a genuine concern. It so simple to understand that its about a special unique compund of NO, not NO itself.

think about it, if you are supporting the company, you are supporting their product. am i wrong? smh
yes NO is free but r&d is not. like common sense, it free but you dont have any. lol

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals